Ampio Pharmaceuticals Inc

  • Health Technology
  • Pharmaceuticals: Other
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing


$0.171 -

Extented Hours




0.1605 - 0.1729


0.1502 - 1.98

Join Discuss about AMPE with like-minded investors

@DarkPoolAlgo #Dark Pool Charts

/*============================================= = Tuesday, June 15, 2021 = =============================================*/ Futures Up/Down % Last Dow -3.00 0.01% 34,272 S&P 500 2.25 0.05% 4,248 Nasdaq 10.50 0.07% 14,127 Another day, another record for the S&P 500, with futures looking to a slightly higher open ahead of a key round of economic data (monthly retail sales at 8:30 AM along with the producer prices index (PPI) inflation reading, which follows the “hotter” CPI report last week) while investors await results of the two-day FOMC meeting tomorrow afternoon. The central bank will make an announcement on interest rates Wednesday, followed by a news conference from Fed Chairman Jerome Powell. Stocks in the U.S. were slightly higher Monday in a listless, tight trading range all day prior to a surge in the final minutes of trading that took most major averages higher, allowing the S&P 500 and Nasdaq to close at record highs led by gains in large cap tech. In Asian markets, The Nikkei Index rose 279 points to 29,441, the Shanghai Index fell -33 points to 3,556, and the Hang Seng Index dropped 203 points to 28,638. In Europe, the German DAX is higher by around 70 points to 15,740, while the FTSE 100 is up about 20 points to 7,165. It should be a relatively quiet day again with all eyes on tomorrows FOMC meeting. Events Calendar for Today 7:45 AM ET ICSC Weekly Retail Sales 8:30 AM EST Producer Price Index (PPI) MoM for May…est. 0.6% 8:30 AM EST Producer Price Index (PPI) YoY for May…est. 6.3% 8:30 AM EST PPI Ex: Food & Energy (core) MoM for May…est. 0.5% 8:30 AM EST PPI Ex: Food & Energy (core) YoY for May…est. 4.8% 8:30 AM EST Advance Retail Sales MoM for May…est. (-0.7%) 8:30 AM EST Retail Sales Less Autos MoM for May…est. 0.2% 8:55 AM ET Johnson/Redbook Weekly Sales 9:15 AM EST Industrial Production MoM for May…est. 0.6% 9:15 AM EST Capacity Utilization for May…est. 75.1% 10:00 AM EST Business Inventories MoM for April…est. (-0.1%) 10:00 AM EST NAHB Housing Market Index for June…est. 83 4:00 AM EST Net Long-term TIC Flows for April 4:30 PM ET API Weekly Inventory Data Earnings Calendar: Earnings Before the Open: $KPLT Earnings After the Close: $ATEX, $HNST, $HRB, $LZB, $ORCL, $STEP, $VOLT Other Key Events: Citigroup European Healthcare Conference (virtual), 6/14-6/16 European Hematology Association (EHA) Virtual Meeting, 6/9-6/17 FBN Securities Valley tech Tour (virtual), 6/14-6/15 Northland Customer Engagement SaaS Conference (virtual), 6/15-6/16 Oppenheimer 21st Annual Consumer Growth and E-Commerce Conference (virtual), 6/15-6/16 China Retail Sales for May Market Closing Prices Yesterday The S&P 500 Index gained 7.71 points, or 0.18%, to 4,255.15 The Dow Jones Industrial Average fell -85.85 points, or 0.25%, to 34,393.75 The Nasdaq Composite jumped 104.72 points, or 0.74%, to 14,174.14 The Russell 2000 Index declined -9.66 points, or 0.41% to 2,326.15 Macro Up/Down Last Nymex 0.46 71.34 Brent 0.47 73.33 Gold -1.45 1,864.75 EUR/USD 0.0005 1.2125 JPY/USD -0.03 110.04 10-Year Note -0.014 1.487% World News Germany May CPI: m/m 0.5% in line; y/y 2.5% in line; HICP m/m 0.3% in line; y/y 2.4% in line France May CPI: m/m 0.3% in line; y/y 1.4% in line; HICP m/m 0.3% vs 0.4% cons; y/y 1.8% in line Italy May CPI: m/m 0.0 in line; y/y 1.3% in line; HICP m/m -0.1% vs 0.0% cons; y/y 1.2% vs 1.3% consensus Sector News Breakdown Consumer Kohl’s ($KSS) said it sees FY sales +mid-high teens vs 2020, below the consensus of up +20.85% Vroom, Inc. ($VRM) announces proposed convertible senior notes offering/to offer $500 mln of convertible senior notes due 2026 Spirit Airlines ($SAVE) estimates its load factor for Q2 will be about 84.0%, total operating expenses, excluding special items, for q2 2021 are tracking towards better end of co’s initial guidance; now expects its Ebitda margin, excluding special items, for q2 of 2021 to be modestly positive; expects that air travel demand will continue to gradually recover in 2021 H&M shares slipped after Q2 sales were lower than expected, hurt by China and European restrictions; Q2 sales were up 62% year on year to SEK 46.51 bln ($5.59 bln), but still down 19% – when compared with two years earlier Ford ($F) says production of 2021 Ford Bronco is underway at the Michigan assembly plant Energy, Industrials and Materials FedEx Corp ($FDX) increased quarterly cash dividend by $0.10 per share, or 15% Mosaic ($MOS) announced its May 2021 sales revenue and volumes May Potash sales volumes in thousands of tons 891 versus 810 in May of last year Fastenal ($FAST) downgraded to Underweight from Equal Weight at Morgan Stanley Financials Discover Financial Services ($DFS) credit card delinquency rate 1.01% at may end vs 1.12% at April end; credit card charge-off rate 1.78% at may end vs 1.54% at April end Capital One Financial ($COF) May domestic credit card net charge-offs rate 2.33 % vs 2.40% in April; delinquencies rate for auto 3.14% at May end vs 2.74% at April end Blucora $(BCOR) raises Q2 non-GAAP EPS view to $1.12-$1.21 from $0.94-$1.11 and ups revenue view to $250.0-$254.5M from $238M-$249M (vs. est. $243.4M) MicroStrategy ($MSTR) has filed a registration statement with the SEC for the potential offering of its class A common shares Principal Financial ($PFG) downgraded to Neutral from Overweight at Piper Sandler Arbor Realty ($ABR) 6M share Spot Secondary priced at $18.65 Alexandria Real Estate ($ARE) 7M share Spot Secondary priced at $184.00 Ellington Residential ($EARN)25M share Spot Secondary priced at $13.20 Rowe Price ($TROW) declares special cash dividend of $3.00 per share Healthcare Biogen ($BIIB) announces topline results from phase 3 gene therapy study in Choroideremia; says phase 3-star study did not meet primary or key secondary endpoints Sage Therapeutics ($SAGE) and Biogen ($BIIB) announce positive pivotal phase 3 results for zuranolone, an investigational two-week, once-daily therapeutic being evaluated for major depressive disorder; rapid onset of treatment effect was seen in hamd-17 results at days 3, 8, and 12 AstraZeneca ($AZN) announces that its antibody cocktail, AZD7442, didn’t achieve a statistically significant reduction in the risk of symptomatic COVID-19 after exposure to the virus, failing to meet primary endpoint of the STORM CHASER trial Ampio Pharmaceuticals ($AMPE) receives approval to expand enrollment of its ap-019 phase ii study to India; phase ii study will utilize inhaled Ampion to treat those suffering from respiratory distress due to covid-19 NanoString Technologies (NSTG) and the Parker Institute for Cancer Immunotherapy ($PICI) are collaborating on an expansive molecular characterization project for cellular therapies Novavax ($NVAX) announces positive results from first study of influenza vaccine and covid-19 vaccine candidate administered simultaneously and that study demonstrated no early safety concerns C4 Therapeutics ($CCCC) files to sell 4.25M shares of common stock Rapt Therapeutics ($RAPT) offers to sell $125M in common stock Technology, Media & Telecom PING Identity Holding ($PING) files prospectus related to offering of 32.7 mln shares of common stock by selling stockholders Vimeo ($VMEO) says May avg. revenue per user up 18% and May total revenue up 42% Applied Materials ($AMAT) files debt securities shelf

125 Replies 10 👍 9 🔥

@Navneet #droscrew

$ampe 2 calls jan 15 0.05

125 Replies 15 👍 11 🔥

Key Metrics

Market Cap

37.78 M



Avg. Volume

3.10 M

Shares Outstanding

227.19 M



Public Float


Next Earnings Date


Next Dividend Date

Company Information

Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK). Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need. Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035. In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

CEO: Michael Macaluso


HQ: 373 Inverness Pkwy Ste 200 Englewood, 80112-5898 Colorado

Related News